Skip to main content
. Author manuscript; available in PMC: 2021 Apr 6.
Published in final edited form as: J Med Chem. 2020 Feb 14;63(5):2489–2510. doi: 10.1021/acs.jmedchem.9b01442

Figure 6. Biological evaluation of compound 24.

Figure 6.

A) Biotin-streptavidin pulldown assay using lysate from the M14 melanoma cell line and biotinylated Bim peptide (BL-Bim) after treatment with 100 μM of compound 24 and its methyl ester analogue, 30r. B) Dose dependent and selective disruption of BL-Bim and Mcl-1/Bfl-1 interactions by compound 24. Complexes of BL-Bim and endogenous anti-apoptotic proteins were analyzed by western blot. C) Eμ-Myc lymphoma cell lines (Mcl-1, Bfl-1, Bcl-2, and Bcl-xL) treated for 24 hours with compounds 24 and 30r, cell death analyzed by flow cytometry. Significance determined by two-tailed t-test compared with DMSO (0 μM) controls of respective cell lines (*, p < 0.05; **, p < 0.005). Data represents mean and SEM from 3 independent experiments.